TNF and infection: There is no evidence to date that biologic treatment is contributory to neonatal cytopenias.31,32 Transplacental transfer of anti-TNF (infliximab, adalimumab) increases throughout pregnancy as IgG monoclonal antibodies are able to cross the placenta as it matures33; but this has not transcribed to an increase in infection risk in offspring.34